BLT
Benitec Biopharma
- Short interest
- 0.01%
- 0.00 pp 30d
- as of 8 Jan 2020
- Reported shorts
- 45.6K
- Shares on issue
- 321.287M
Benitec Biopharma (BLT) financials
Results, ratios and statements
Fundamentals
Our data providers hold no financial statements for BLT (last checked 15 Oct 2026). The company's own filings are listed below.
Financial reports
The company's own filings, newest first
- BB-301: a silence and replace AAV-based vector for the treatment of oculopharyngeal muscular dystrophyFinancial Report31 Dec 2021via crawler
- BB-301: A Single “Silence and Replace” AAV-Based Vector for the Treatment of Oculopharyngeal Muscular Dystrophy (OPMD)Financial Report31 Dec 2018via crawler
- Towards Development of a ‘Silence and Replace’ Based Approach for the Treatment of Oculopharyngeal Muscular DystrophyFinancial Report31 Dec 2017via crawler
- Gene therapy for oculopharyngeal muscular dystrophyFinancial Report31 Dec 2017via crawler
- Towards Development of a ‘Silence and Replace’ Based Approach for the Treatment of Oculopharyngeal Muscular Dystrophy.Financial Report31 Dec 2017via crawler
- PABPN1 gene therapy for oculopharyngeal muscular dystrophyFinancial Report31 Dec 2017via crawler
- Toxicology evaluation of TT-034 demonstrates durable expression in hepatic tissues without long term adverse effects on endogenous miRNA levelsFinancial Report31 Dec 2016via crawler
- A comparison of scAAV8-TT034 mediated transduction and shRNA expression in human liver biopsy samples versus a chimeric mouse model with humanized liverFinancial Report31 Dec 2016via crawler